CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Real-time Euronext Paris 08:38:00 02/07/2024 pm IST | ||
| 4.775 EUR | -20.75% |
|
| Current month | +6.83% | ||
| 1 month | +110.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 02/24/02 | 4.775 | -20.75% |
| 01/24/01 | 6.025 | +6.83% |
| 28/24/28 | 5.64 | +5.22% |
| 27/24/27 | 5.36 | -5.96% |
| 26/24/26 | 5.7 | -21.92% |
Real-time Euronext Paris
Last update July 02, 2024 at 08:38 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 6FLMB | |
| ISIN | NLBNPNL2IDY7 |
| Date issued | 20/09/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.87 € |
|---|---|
| Lowest since issue | 0.308 € |
| Spread | 0.13 € |
| Spread % | 2.84% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,005
DKK
Average target price
952.2
DKK
Spread / Average Target
-5.22%
- Stock Market
- Certificates
- 6FLMB Certificat
